These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2291838)

  • 21. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men.
    Mori TA; Burke V; Puddey IB; Watts GF; O'Neal DN; Best JD; Beilin LJ
    Am J Clin Nutr; 2000 May; 71(5):1085-94. PubMed ID: 10799369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fish oil supplementation does not lower plasma cholesterol in men with hypercholesterolemia. Results of a randomized, placebo-controlled crossover study.
    Wilt TJ; Lofgren RP; Nichol KL; Schorer AE; Crespin L; Downes D; Eckfeldt J
    Ann Intern Med; 1989 Dec; 111(11):900-5. PubMed ID: 2683921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia.
    Liacouras CA; Coates PM; Gallagher PR; Cortner JA
    J Pediatr; 1993 Mar; 122(3):477-82. PubMed ID: 8441109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-molecular-weight hydroxypropylmethylcellulose. A cholesterol-lowering agent.
    Dressman JB; Adair CH; Barnett JL; Berardi RR; Dunn-Kucharski VA; Jarvenpaa KM; Parr DD; Sowle CA; Swidan SZ; Tobey SW
    Arch Intern Med; 1993 Jun; 153(11):1345-53. PubMed ID: 8507125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Effects of Cucumis sativus Seed Extract on Serum Lipids in Adult Hyperlipidemic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Soltani R; Hashemi M; Farazmand A; Asghari G; Heshmat-Ghahdarijani K; Kharazmkia A; Ghanadian SM
    J Food Sci; 2017 Jan; 82(1):214-218. PubMed ID: 27886382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
    Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
    J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
    Carlsen SM; Rossvoll O; Bjerve KS; Følling I
    J Intern Med; 1996 Mar; 239(3):227-33. PubMed ID: 8772621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
    März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW
    Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.
    Ojala JP; Helve E; Tikkanen MJ
    Cardiology; 1990; 77 Suppl 4():39-49. PubMed ID: 2073671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
    Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
    Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
    Calabresi L; Donati D; Pazzucconi F; Sirtori CR; Franceschini G
    Atherosclerosis; 2000 Feb; 148(2):387-96. PubMed ID: 10657575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.